SequelSEC

QuidelOrtho Corp QDEL

In Vitro & In Vivo Diagnostic Substances · CIK 0001906324 · Fiscal year ends 0101

AnnualQuarterlyTTM
Revenue
$2.73B
Fiscal year ended 2025-12-28
Operating income
-$919.20M
Fiscal year ended 2025-12-28
Free cash flow
-$83.00M
Fiscal year ended 2025-12-28

QuidelOrtho Corp (QDEL) reported revenue of $2.73B and net income of -$1.13B for the fiscal year ended 2025-12-28. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from QuidelOrtho Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

QuidelOrtho Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-282024-12-292023-12-312023-01-012022-01-022021-01-03
Revenue$2.73B$2.78B$3.00B$3.27B$1.70B$1.66B
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$919.20M-$1.96B$139.10M$843.70M$906.00M$1.06B
Net income-$1.13B-$2.05B-$10.10M$548.70M$704.20M$810.30M
Research & development$186.20M$218.70M$245.00M$187.90M$95.70M$84.30M
Weighted-average diluted sharesshares 67.80Mshares 67.20Mshares 66.80Mshares 57.40Mshares 42.90Mshares 43.60M
Pretax income-$1.11B-$2.13B-$29.10M$735.90M$900.30M$1.04B
Income tax expense$24.10M-$79.50M-$19.00M$187.20M$196.10M$230.00M
Diluted EPS$-16.69$-30.54$-0.15$9.56$16.43$18.60
Selling, general & administrative$746.30M$766.80M$763.20M$621.00M$239.60M$180.70M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

QuidelOrtho Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-282024-12-292023-12-312023-01-012022-01-022021-01-03
Cash & equivalents$169.80M$98.30M$118.90M$292.90M$802.80MUnavailable
Total assets$5.77B$6.42B$8.56B$8.86B$2.43BUnavailable
Current assets$1.45B$1.22B$1.31B$1.58B$1.44BUnavailable
Total liabilities$3.85B$3.44B$3.56B$3.92B$501.00MUnavailable
Current liabilities$966.10M$998.80M$833.80M$1.01B$323.50MUnavailable
Total equity incl. NCI$1.92B$2.98B-$30.00M-$67.60M$400.00K$1.33B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$577.60M$533.70M$577.80M$524.10M$198.80MUnavailable
Accounts receivable$417.00M$282.40M$303.30M$453.90M$378.00MUnavailable
Goodwill$0$649.50M$2.49B$2.48B$337.00MUnavailable
Long-term debt$2.47B$2.14B$2.27B$2.43B$700.00KUnavailable
Accounts payable$279.40M$246.00M$294.80M$283.30M$101.50MUnavailable

Cash flow

QuidelOrtho Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-282024-12-292023-12-312023-01-012022-01-022021-01-03
Operating cash flow$105.20M$83.00M$280.20M$885.30M$805.90M$629.70M
Capital expenditures$188.20M$195.10M$209.30M$140.90M$292.80M$64.90M
Investing cash flow-$192.70M-$149.90M-$187.60M-$1.64B-$319.50M-$63.30M
Financing cash flow$155.80M$48.80M-$265.80M$252.00M-$173.10M-$130.30M
Net change in cash$71.30M-$21.00M-$174.40M-$508.90M$312.90M$437.10M
Stock-based compensation$45.90M$42.10M$51.60M$48.40M$25.40M$21.00M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$0$7.20M$74.30M$103.50M$43.70M
Depreciation & amortization$442.00M$453.40M$457.20M$283.60M$52.70M$48.80M

Derived

QuidelOrtho Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-282024-12-292023-12-312023-01-012022-01-022021-01-03
Free cash flow-$83.00M-$112.10M$70.90M$744.40M$513.10M$564.80M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-33.7%-70.5%4.6%25.8%53.3%63.8%
FCF margin-3.0%-4.0%2.4%22.8%30.2%34.0%
SBC / revenue1.7%1.5%1.7%1.5%1.5%1.3%
Current ratio1.50x1.22x1.57x1.56x4.45xUnavailable
Revenue YoY growth-1.9%-7.2%-8.2%92.3%2.2%Unavailable
Net margin-41.5%-73.7%-0.3%16.8%41.5%48.8%
R&D / revenue6.8%7.9%8.2%5.8%5.6%5.1%
CapEx / revenue6.9%7.0%7.0%4.3%17.2%3.9%
Long-term debt / equity1.29xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable25.4%21.8%22.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open QDEL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ACHV AWHL BMRA BZYR CDIO CLDX ICCC IDXX IMDX LNTH MYGN NEOG

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-12-31

Difference 5035900000 exceeds tolerance 8563100.000. Presentation or filing-vintage differences need review.

balance equationreview2023-01-01

Difference 5002200000 exceeds tolerance 8855800.000. Presentation or filing-vintage differences need review.

balance equationreview2022-01-02

Difference 1929000000 exceeds tolerance 2430400.000. Presentation or filing-vintage differences need review.